These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19929980)

  • 1. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
    Parhofer KG; Birkeland KI; DeFronzo R; Del Prato S; Bhaumik A; Ptaszynska A
    Int J Clin Pract; 2010 Jan; 64(2):160-8. PubMed ID: 19929980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
    Agabiti-Rosei E; Manolis A; Zava D; Omboni S;
    Adv Ther; 2014 Feb; 31(2):217-33. PubMed ID: 24415271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
    Raskin P; Guthrie R; Flack J; Reeves R; Saini R
    J Hum Hypertens; 1999 Oct; 13(10):683-7. PubMed ID: 10516738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
    Sowers JR; Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Weber MA;
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):470-80. PubMed ID: 16849900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
    Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
    J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
    Taguchi I; Toyoda S; Takano K; Arikawa T; Kikuchi M; Ogawa M; Abe S; Node K; Inoue T
    Hypertens Res; 2013 Jul; 36(7):608-13. PubMed ID: 23425956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
    Sun NL; Jing S; Chen J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul; 33(7):618-21. PubMed ID: 16080809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
    Krone W; Hanefeld M; Meyer HF; Jung T; Bartlett M; Yeh CM; Rajman I; Prescott MF; Dole WP
    J Hum Hypertens; 2011 Mar; 25(3):186-95. PubMed ID: 20376075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.